• Home
• About Lipoxen
• Our Technologies
• Pipeline
• Partnering
• Corporate Governance
• Investor Centre
• News
  • FAQ
  • Contact us
  • Careers

Lipoxen to present at the SMi Drug Delivery Global Summit

22 September 2008

Presentation to discuss Lipoxen's clinical stage products and technology platforms for the
delivery of siRNA therapeutics and DNA vaccines

London, UK, 22 September 2008 - Lipoxen PLC, (AIM:LPX) a biopharmaceutical company
specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, today announces that Chief Operating Officer, Dr Peter Laing, will present at the SMi Drug Delivery Global Summit. The conference takes place September 22 - 23, 2008 at The Copthorne Tara Hotel, London, UK.

Dr Laing's presentation, entitled Delivery of protein and peptide drugs with polysialic acid: a new technology platform in the clinic, will give a brief corporate overview of Lipoxen and discuss topics such as Lipoxen's versatile enabling technology, PolyXenTM, which uses polysialic acid (PSA) to prolong the active life, and improve the pharmacokinetics, of therapeutic peptides and proteins. Dr Laing will also discuss Lipoxen's liposomal therapeutics platforms for the liposomal delivery of siRNA therapeutics and DNA vaccines using non-toxic vehicles suitable for chronic administration.

Dr Laing's presentation will take place on Monday, September 22nd, at 11:40 a.m. For more information on the conference, of which Lipoxen is also a sponsor, please visit http://www.smi-online.co.uk/events/overview.asp?is=4&ref=2944.

- Ends -

Enquiries